Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 2.39 is in line with its 5-year average of 2.61, around the middle of its 5-year range (0.06–6.47).
As of the fiscal period ended Tuesday, June 30, 2026. 29.15% below its 12-month average of 3.38.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.39.
QUICK RATIO (ACID-TEST)
2.39
QUICK RATIO (ACID-TEST) AVG TTM
3.38
QUICK RATIO (ACID-TEST) AVG 3Y
3.81
QUICK RATIO (ACID-TEST) AVG 5Y
2.61
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.15%
CURRENT VS 3Y AVG
-37.23%
CURRENT VS 5Y AVG
-8.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.20
median of 756 covered companies
CURRENT VS SECTOR MEDIAN
-25.08%
vs the sector median at left
Genelux Corporation
Market Cap
$115.69M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.38
3Y Avg
3.81
5Y Avg
2.61
Market Cap
$115.65M
Quick Ratio (Acid-Test)
1.31
TTM Avg
1.18
3Y Avg
1.49
5Y Avg
3.22
Market Cap
$111.21M
Quick Ratio (Acid-Test)
0.65
TTM Avg
1.74
3Y Avg
2.55
5Y Avg
2.19
Market Cap
$116.82M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$117.53M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$118.05M
Quick Ratio (Acid-Test)
13.31
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$113.61M
Quick Ratio (Acid-Test)
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$112.77M
Quick Ratio (Acid-Test)
11.47
TTM Avg
9.04
3Y Avg
10.96
5Y Avg
10.73
Market Cap
$121.23M
Quick Ratio (Acid-Test)
14.06
TTM Avg
14.20
3Y Avg
21.81
5Y Avg
28.51
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $115.69M | 2.39 | 3.38 | 3.81 | 2.61 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.65M | 1.31 | 1.18 | 1.49 | 3.22 |
| BGM Group Ltd. (BGM)vs › | $111.21M | 0.65 | 1.74 | 2.55 | 2.19 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | 13.40 | 10.04 | 7.53 | 8.95 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 6.49 | 6.44 | 8.52 | 8.53 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | 13.31 | 17.30 | 10.78 | 9.73 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.61M | 3.36 | 3.23 | 4.24 | 6.08 |
| MaxCyte, Inc. (MXCT)vs › | $112.77M | 11.47 | 9.04 | 10.96 | 10.73 |
| Seer, Inc. (SEER)vs › | $121.23M | 14.06 | 14.20 | 21.81 | 28.51 |
| Cibus, Inc. (CBUS)vs › | $122.13M | 1.62 | 0.78 | 1.43 | 2.39 |
Quick Ratio
2.39
Excludes inventory
Current Ratio
2.39
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 2.39 |
| 2026-03-31 | 3.68 |
| 2025-12-31 | 2.43 |
| 2025-09-30 | 4.20 |
| 2025-06-30 | 4.18 |
| 2025-03-31 | 4.67 |
| 2024-12-31 | 4.57 |
| 2024-09-30 | 6.47 |
| 2024-06-30 | 6.01 |
| 2024-03-31 | 2.72 |
| 2023-12-31 | 3.69 |
| 2023-09-30 | 3.56 |
| 2023-06-30 | 3.64 |
| 2023-03-31 | 1.14 |
| 2022-12-31 | 0.06 |
| 2022-09-30 | 0.13 |
| 2022-06-30 | 0.20 |
| 2022-03-31 | 0.28 |
| 2021-12-31 | 0.26 |
| 2021-09-30 | 0.26 |
| 2021-06-30 | 0.26 |
| 2021-03-31 | 0.67 |
| 2020-12-31 | 0.79 |
| 2020-09-30 | 0.79 |
| 2020-06-30 | 0.79 |
| 2020-03-31 | 0.00 |
